Abstract
The hemodynamic determination of operability in atrial septal defect (ASD) with severe pulmonary hypertension is problematic. Therefore, we perform an open lung biopsy prior to the corrective surgery in cases with pulmonary vascular resistance greater than 8 units ? m2 and/or pulmonary arterial peak pressure greater than 70 mmHg. We present 4 cases showing occlusion of more than 70% of the small pulmonary arteries and arterioles by musculoelastosis, thromboembolism and mixed-type (musculoelastosis and plexogenic arteriopathy) which was considered borderline in terms of operability. After complete closure of the ASD and postoperative long-term oral prostacyclin (PGI2) therapy, pulmonary artery peak pressure decreased from 110–72 (mean 84) to 105–45 (mean 74) mmHg immediately after operation and 65–40 (mean 57) mmHg after PGI2 therapy. The New York Heart Association functional status of the patients improved from class II–III to class I with oral PGI2 only. Our cases demonstrate that despite more than 70% occlusion of the small pulmonary arteries and arterioles, surgery and long-term PGI2 therapy can reduce pulmonary artery pressure and improve the quality of life.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yamaki S, Horiuchi T, Miura M, Haneda K, Ishizawa E, Suzuki Y. Secundum atrial septal defect with severe pulmonary hypertension. Open lung biopsy diagnosis of operative indication. Chest 1987; 91: 33–8.
Wagenvoort CA, Keutel J, Mooi WJ, Wagenvoort N. Longitudinal smooth muscle in pulmonary arteries: Occurrence in congenital heart disease. Virchows Arch A Pathol Anat Histopathol 1984; 404: 265–74.
Yamaki S, Mohri H, Haneda K, Endo M, Akimoto H. Indications for surgery based on lung biopsy in cases of ventricular septal defect and/or patent ductus arteriosus with severe pulmonary hypertension. Chest 1989; 96: 31–9.
Christman BW, McPherson CD, Newman JK, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70–5.
Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858–65.
Saji T, Ozawa Y, Ishikita T, Matsuura H, Matsuo N. Short-term hemodynamic effects of a new oral PGI analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244–7.
Nagaya N, Shimizu Y, Satoh T, Oya H, Uematsu M, Kyotani S, et al. Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart 2002; 87: 304–45.
Yamauchi H, Yamaki S, Fujii M, Iwaki H, Tanaka S. Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect. Ann Thorac Surg 2001; 72: 905–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamauchi, H., Yamaki, S., Fujii, M. et al. Atrial septal defect with borderline pulmonary vascular disease. Jpn J Thorac Caridovasc Surg 52, 213–216 (2004). https://doi.org/10.1007/s11748-004-0112-1
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11748-004-0112-1